SCOPUS 정보 검색 플랫폼

Journal of the National Cancer Institute

Volumn 103, Issue 20, 2011, Pages 1558-

Response: Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

(9) Rini, Brian I a Cohen, Darrel P b Lu, Dongrui R b Chen, Isan b Hariharan, Subramanian c Gore, Martin E d Figlin, Robert A e Baum, Michael S f Motzer, Robert J f

a TAUSSIG CANCER INSTITUTE (United States)

b Research and Development Oncology Prometheus Laboratories (United States)

c Pfizer Ltd (United States)

d INSTITUTE OF CANCER RESEARCH (United Kingdom)

e CEDARS SINAI MEDICAL CENTER (United States)

f MEMORIAL SLOAN KETTERING CANCER CENTER (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; SUNITINIB; VASCULOTROPIN;

BLOOD PRESSURE MONITORING; DIASTOLIC BLOOD PRESSURE; DRUG TARGETING; GENE EXPRESSION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE;

EID: 80054963802 PISSN: 00278874 EISSN: 14602105 Source Type: Journal
DOI: 10.1093/jnci/djr329 Document Type: Letter

Times cited : (5)

References (5)

1
- 79957909038
- Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors
- Rini BI, Schiller JH, Fruehauf JP, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res. 2011;17(11):3841-3849.
- (2011) Clin Cancer Res , vol.17 , Issue.11 , pp. 3841-3849
- Rini, B.I.¹ Schiller, J.H.² Fruehauf, J.P.³

2
- 0347423198
- Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
- DOI 10.1161/01.HYP.0000107251.49515.c2
- Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252. (Pubitemid 37553153)
- (2003) Hypertension , vol.42 , Issue.6 , pp. 1206-1252
- Chobanian, A.V.¹ Bakris, G.L.² Black, H.R.³ Cushman, W.C.⁴ Green, L.A.⁵ Izzo Jr., J.L.⁶ Jones, D.W.⁷ Materson, B.J.⁸ Oparil, S.⁹ Wright Jr., J.T.¹⁰ Roccella, E.J.¹¹

3
- 77949894217
- Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599
- Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol. 2010;28(6):949-954.
- (2010) J Clin Oncol , vol.28 , Issue.6 , pp. 949-954
- Dahlberg, S.E.¹ Sandler, A.B.² Brahmer, J.R.³ Schiller, J.H.⁴ Johnson, D.H.⁵

4
- 80054879487
- Axitinib pharmacokinetics and blood pressure changes in front-line metastatic renal cell carcinoma (RCC) patients
- Abstract 907P
- Fishman MN, Carducci M, Bair AH, Chen Y, Rini BI. Axitinib pharmacokinetics and blood pressure changes in front-line metastatic renal cell carcinoma (RCC) patients. Ann Oncol. 2010;21(suppl 8):viii284. Abstract 907P.
- (2010) Ann Oncol. , Issue.21 SUPPL. 8
- Fishman, M.N.¹ Carducci, M.² Bair, A.H.³ Chen, Y.⁴ Rini, B.I.⁵

5
- 77957231200
- Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels
- Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56(4):675-681.
- (2010) Hypertension , vol.56 , Issue.4 , pp. 675-681
- Kappers, M.H.¹ Van Esch, J.H.² Sluiter, W.³ Sleijfer, S.⁴ Danser, A.H.⁵ Van Den Meiracker, A.H.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.